Reach-hfpef trial

Author: xjcb

August undefined, 2024

WebMar 8, 2024 · The complex pathophysiology of heart failure with preserved ejection fraction (HFpEF) makes it a diagnostic and therapeutic challenge. ... but there is no clinical trial evidence to support its use at the higher range of the LVEF spectrum. 1 In an individual patient-level meta-analysis of double-blind randomized trials, ... WebSep 1, 2024 · The REHAB-HFpEF trial will determine whether a novel physical rehabilitation intervention will improve the primary outcome of combined all-cause rehospitalizations and mortality and the secondary outcome of major mobility disability during 6-month follow-up in patients hospitalized for heart failure and preserved ejection fraction (HFpEF), which is …

Study aims to REACH out to heart failure patients

WebAug 27, 2024 · With 5988 patients randomized in a 1:1 ratio to 10 mg empagliflozin or placebo therapy, the trial, which had a median follow-up of 26.2 months, is the first to provide evidence of a therapy with the potential to significantly reduce the risk of heart failure hospitalization and cardiovascular death in patients with HFpEF. WebApr 1, 2024 · The findings support the feasibility and rationale for delivering the REACH-HF facilitated home-based rehabilitation intervention for patients with heart failure with preserved ejection fraction and their caregivers and progression to a full multicentre randomised clinical trial to test its clinical effectiveness and cost-effectiveness. … biomed research international sijie tan

Effect of Vericiguat vs Placebo on Quality of Life in Patients With ...

WebA pilot randomised trial of home-based rehabilitation compared to usual care in patients with heart failure with preserved ejection fraction and their caregiver’s (REACH-HFpEF study): a process ... WebRehabilitation Enablement in Chronic Heart Failure – a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single-centre pilot randomised controlled trial. BMJ Open, 2016. Read the full rationale and protocol here. 2015 WebThe REACH-HF intervention consisted of self-help manual for patients and caregivers, facilitated over 12 weeks by trained healthcare professionals. Interviews were conducted following completion... daily salt intake in grams

REACH-HFpEF Study - A randomised controlled trial of a …

Study aims to REACH out to heart failure patients

WebNov 10, 2024 · Study aims to REACH out to heart failure patients. The Universities of Dundee, Glasgow, Exeter, Birmingham, Cambridge, and York have received £2.4 million to … WebMay 22, 2024 · The REACH-HFpEF pilot study findings support the feasibility and acceptability of the home-based REACH-HF rehabilitation intervention in patients with … biomed research international issn noWebAug 7, 2024 · This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and … biomed research international journal

"WebStrengths and limitations of this study. Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) is the first comprehensive home-based, self-management cardiac … " - Reach-hfpef trial

Reach-hfpef trial

A randomised controlled trial of a facilitated home-based ...

WebOct 20, 2024 · The VITALITY-HFpEF trial failed to show that vericiguat improved a physical limitation score. Description: The goal of the trial was to evaluate the oral soluble guanylate cyclase stimulator vericiguat compared with placebo among patients with heart failure with preserved ejection fraction (HFpEF). Study Design Randomized Parallel Double-blind WebCurrent active members - Rehabilitation Enablement in Chronic Heart Failure REACH-HF Current active members Dr Hayes Dalal Prof Rod Taylor Prof Colin Greaves Prof Patrick Doherty Dr Samantha van Beurden Dr Sinead McDonagh Dr Rosina Cross Pam Baxter Tori Hammond Elena Fantozzi Dr Alan McLeod Miriam Noonan

Did you know?

WebAug 27, 2024 · In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in ...

WebThe REACH-HFpEF pilot trial was a single-centre study with the aim of assessing the feasibility of under-taking a multicentre randomised trial to assess the clin-ical … WebSep 3, 2024 · Background Reach Out is a factorial trial studying multicomponent behavioral interventions to reduce blood pressure in hypertensive emergency department patients. The original study protocol was ...

Webintervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single- centre pilot randomised … WebIntroduction. Heart failure with preserved ejection fraction (HFpEF) is a major global public health issue. 1,2 HFpEF can be defined as a clinical syndrome when the heart cannot pump the blood adequately without the cardiac filling pressures elevation. 3 Since 2007 when a consensus statement the Heart Failure Association (HFA) of the European Society of …

WebAug 27, 2024 · Results of the EMPEROR-Preserved trial indicate use of empagliflozin (Jardiance) was associated with a 21% reduction in risk of the composite end point of …

WebThe REACH-HFpEF Trial Research type Research Study Full title Randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with … biomed research international h indexWebApr 12, 2024 · The Systolic Hypertension in Elderly Program (SHEP) trial included 4736 people with more than 60 years old and demonstrated that lowering BP from 170/77 to 143/78 mm Hg reduced HF events by 48% [... biomed research international 官网WebFeb 1, 2024 · Our REACH-HF intervention offers a new evidence-based cardiac rehabilitation option that could increase uptake of cardiac rehabilitation in patients with heart failure not … biomed research international submissionWebREACH-HFpEF trial with process evaluation NIHR127312: A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with … biomed research international 几区WebAug 27, 2024 · Heading into the European Society of Cardiology (ESC) Congress 2024, all eyes appeared to be on empagliflozin as cardiologists and other clinicians awaited the results of the EMPEROR-Preserved trial, which Eli Lilly and Company and Boehringer Ingelheim announced as the first and only successful trial for heart failure with preserved … biomed research international 分区WebMar 22, 2024 · Methods: This was a post hoc analysis of the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) trial. Enrolled patients had chronic HF with left ventricular ejection fraction >40% and New York Heart Association (NYHA) class II-IV symptoms with an elevated B-type … dailys and dashWebMar 17, 2024 · Gu J, Yin Z, Zhang J and Wang C (2024) Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension, International Journal of Cardiology, 10.1016/j.ijcard.2024.11.087, 306, (140-145), Online publication date: 1-May … biomed research international とは